Haleon: targets confirmed after strong H1
(CercleFinance.com) - British consumer healthcare group Haleon, a spin-off from the sector giant GSK, today announced H1 sales that are up 13% at 5.
2 billion pounds.
Organic sales growth reached 11.6% in the first six months of the year, with a 3.7% rise in prices and a 7.9% rise in volumes.
In a statement, Haleon highlighted the sound performance of some of its non-prescription medicines, such as Panadol (paracetamol), Theraflu (cold and flu), Otrivin (nasal decongestant), Advil (painkiller) and Centrum (multi-vitamins).
Adjusted operating profit rose 21% to nearly 1.2 billion pounds in the quarter, including a 15.5% increase at constant exchange rates.
The company also confirmed target organic growth of 6% to 8% for the full year.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
2 billion pounds.
Organic sales growth reached 11.6% in the first six months of the year, with a 3.7% rise in prices and a 7.9% rise in volumes.
In a statement, Haleon highlighted the sound performance of some of its non-prescription medicines, such as Panadol (paracetamol), Theraflu (cold and flu), Otrivin (nasal decongestant), Advil (painkiller) and Centrum (multi-vitamins).
Adjusted operating profit rose 21% to nearly 1.2 billion pounds in the quarter, including a 15.5% increase at constant exchange rates.
The company also confirmed target organic growth of 6% to 8% for the full year.
Copyright (c) 2022 CercleFinance.com. All rights reserved.